Company intelligence / Profile preview

Syngenta

Ownership: Private
Employees: ~56000
Development stage: Commercial

Overview

Syngenta develops and markets commercialized crop protection products—including herbicides, fungicides, insecticides—and seeds with advanced genetic traits. It has a global commercial presence with no clinical pipeline as understood in pharma/biotech.

Therapeutic areas: Other
Modalities: Small moleculeBiologicGenetically modified organism (GMO) seeds and traitsDigital agriculture platforms
Industry: Agriculture & AgTech

Drug pipeline

3 assets

PLINAZOLIN

Commercial

Indications: Insect control

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with academic institutions such as Queensland University for biofuels researchPunjab Agricultural University for rice productivitypartnerships with Myriad Genetics Inc., among others

Beyond the preview

Go deeper on Syngenta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syngenta.

Explore the full profile